What you need to know about Aimovig, a new migraine drug | Science News

Support Science Journalism

Science News is a nonprofit.

Support us by subscribing now.


News

What we know — and don’t know — about a new migraine drug

Aimovig was recently approved for use by the U.S. Food and Drug Administration

By
2:17pm, June 5, 2018
woman with headache

HOPE FOR MIGRAINES?  A new preventive treatment for migraines was recently approved by the U.S. Food and Drug Administration.

Migraines have plagued humans since time immemorial. Now a new migraine prevention treatment, recently approved by the U.S. Food and Drug Administration, promises long-awaited relief from the debilitating condition. But whether the drug will turn out to be a real solution for the 1 in 7 Americans who suffer from migraines, severe headaches that often come with nausea and visual auras, isn’t yet clear. Here’s what we know, and don’t know, about the new therapy.

How does the drug work in the body?

The new drug, Aimovig, generically called erenumab, is a type of monoclonal antibody treatment, a class of medications that resemble the antibodies that the body naturally produces to bind to infectious pathogens.

These treatments work by using specially designed antibodies to target specific proteins and their receptors that contribute to

This article is only available to Science News subscribers. Already a subscriber? Log in now.
Or subscribe today for full access.

Get Science News headlines by e-mail.

More Context posts

From the Nature Index Paid Content